Unraveling mRNA delivery bottlenecks of ineffective delivery vectors by co-transfection with effective carriers
-
Published:2024-09
Issue:
Volume:202
Page:114414
-
ISSN:0939-6411
-
Container-title:European Journal of Pharmaceutics and Biopharmaceutics
-
language:en
-
Short-container-title:European Journal of Pharmaceutics and Biopharmaceutics
Author:
Oude Egberink Rik,
van Schie Deni M.,
Joosten BenORCID,
de Muynck Lisa.T.A.,
Jacobs Ward,
van Oostrum Jenny,
Brock RolandORCID
Reference72 articles.
1. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability;Schoenmaker;Int. J. Pharm.,2021
2. Delivery of RNA therapeutics: the great endosomal escape!;Dowdy;Nucleic Acid Ther.,2022
3. Stability study of mRNA-lipid nanoparticles exposed to various conditions based on the evaluation between physicochemical properties and their relation with protein expression ability;Kamiya;Pharmaceutics,2022
4. The storage and in-use stability of mRNA vaccines and therapeutics: not a cold case;Oude Blenke;J. Pharm. Sci.,2023
5. S. Ndeupen, Z. Qin, S. Jacobsen, A. Bouteau, H. Estanbouli, B.Z. Igyártó, The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory, iScience, 24 (2021) 103479-103479.